CLINICAL_TRIALS
trial_result
· 2021-06-11
Clinical Trial Update: BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis [Phase 2, Phase 3]
Summary
Phase 2/3 trial update for SPESOLIMAB (BI655130) as induction therapy in adults with moderate-to-severe ulcerative colitis; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Colitis, Ulcerative | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-06-11